Chronic hepatitis C therapy: A rare complication revisited

BMJ Case Reports

Volumn , Issue , 2013, Pages

  Alsabbagh, Mohammed Eyad Yaseen ^a   Eisa, Naseem ^b   Alraiyes, Abdul Hamid ^c   Alraies, M Chadi ^b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BICARBONATE; C PEPTIDE; GLUCOSE; GLUTAMATE DECARBOXYLASE ANTIBODY; INSULIN; PEGINTERFERON ALPHA2A; RIBAVIRIN; TELAPREVIR; VIRUS RNA;

ABDOMINAL PAIN; ABDOMINAL TENDERNESS; ABNORMAL LABORATORY RESULT; ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; BICARBONATE BLOOD LEVEL; CASE REPORT; CLINICAL FEATURE; DEHYDRATION; DIABETIC KETOACIDOSIS; DRUG ABUSE; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KETONURIA; MALE; MEDICAL HISTORY; PHYSICAL EXAMINATION; POLYDIPSIA; POLYURIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT OUTCOME; VIRUS LOAD; VOMITING;

EID: 84882628964     PISSN: None     EISSN: 1757790X     Source Type: Journal    
DOI: 10.1136/bcr-2013-200514     Document Type: Article

References (7)

1. Jacobson IM, McHutchison JG, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-16.
2. Mandac JC, Chaudhry S, Sherman KE, et al. The clinical and physiological spectrum of interferon-alpha induced thyroiditis: toward a new classification. Hepatology 2006;43:661-72.
3. Fabris P, Betterle C, Floreani A, et al. Development of type 1 diabetes mellitus during interferon alfa therapy for chronic HCV hepatitis. Lancet 1992;340:548.
4. Fattovich G, Giustina G, Favarato S, et al. A survey of adverse events in 11, 241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 1996;24:38-47.
5. Yamada K, Otabe S, Inada C, et al. Nitric oxide and nitricoxide synthase mRNA induction in mouse islet cells by interferon-gamma plus tumor necrosis factor-alpha. Biochem Biophys Res Commun 1993;197:22-7.
6. Nakamura K, Kawasaki E, Abiru N, et al. Trajectories of anti-isletautoantibodies before development of type 1 diabetes in interferon treated hepatitis C patients. Case reports and a literature review. Endocr J 2010;57:947-51.
7. Popescu C, Popescu GA, Arama V. Type 1 diabetes mellitus with dual autoimmune mechanism related to pegylated interferon and ribavirin treatment for chronic HCV hepatitis. J Gastrointestin Liver Dis 2013;22:101-4.